Related Experiment Videos
[Immunological aspects of adverse reactions during treatment with rifampicin]
Abstract:
It has already been established that during the treatment with rifampicin severe adverse reactions may occur, especially mediated by immune mechanisms. The most severe are those followed by renal failure. This type of reactions usually occur in patients that have undergone previous long treatments with the drug (RMP), given intermittently, twice a week, who, after an intermission, take up again the treatment with rifampicin. The symptoms occur after the administration of the first dose of the second course. Three cases are presented in the paper, of renal failure that developed after a new course of rifampicin was started. In spite of the treatment applied, which included hemodialysis, two of the patients died. In all three the indirect Coombs test was positive for anti -- RMP antibodies, and the histopathologic investigation revealed extensive lesions, including necrosis, of the renal tubules. Diagnostic, prognostic, pathogenic and therapeutic aspects of the cases are discussed.
Insights
Severe kidney damage and fatalities can occur when rifampicin (RMP) retreatment is initiated after an interval. This immune-mediated reaction, linked to anti-RMP antibodies, highlights critical risks in RMP therapy.
Area of Science:
- Immunology
- Nephrology
- Pharmacology
Background:
- Rifampicin (RMP) is an antibiotic used to treat tuberculosis.
- Severe adverse reactions, particularly immune-mediated ones, can occur during RMP treatment.
- Renal failure is a severe complication associated with RMP therapy.
Observation:
- This report details three cases of acute renal failure following the reintroduction of RMP after a treatment interruption.
- Symptoms manifested after the first dose of the second RMP course.
- Two patients died despite intensive treatment, including hemodialysis.
Findings:
- All three patients exhibited a positive indirect Coombs test, indicating the presence of anti-RMP antibodies.
- Histopathological examination revealed extensive renal tubule necrosis in all cases.
- The findings suggest an immune-mediated mechanism triggered by RMP re-exposure.
Implications:
- This study underscores the potential for severe, life-threatening immune reactions upon RMP retreatment.
- Early diagnosis and monitoring for anti-RMP antibodies are crucial in patients undergoing intermittent RMP therapy.
- Understanding these pathogenic mechanisms is vital for developing safer therapeutic strategies and improving patient outcomes.